UBE2T

Across TCGA pan-cancer cohorts, UBE2T Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated UBE2T data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher UBE2T Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2T expression acts as an unfavorable survival marker.

OV are the cancer types where UBE2T Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	48	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

UBE2T–OV (OS)

Open the OV breakdown →